Wall Street analysts predict that Xencor, Inc. (NASDAQ:XNCR) will announce earnings of ($0.25) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Xencor’s earnings, with estimates ranging from ($0.29) to ($0.19). Xencor posted earnings per share of $1.13 during the same quarter last year, which would indicate a negative year-over-year growth rate of 122.1%. The company is scheduled to issue its next earnings results on Tuesday, August 1st.

On average, analysts expect that Xencor will report full year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.34) to ($0.92). For the next fiscal year, analysts expect that the company will report earnings of ($1.62) per share, with EPS estimates ranging from ($2.02) to ($1.15). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Xencor.

Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.06. The company had revenue of $4.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a return on equity of 5.98% and a net margin of 18.19%.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded Xencor from a “buy” rating to a “hold” rating in a report on Saturday, April 29th. Nomura assumed coverage on Xencor in a report on Wednesday, March 1st. They issued a “neutral” rating for the company. Wedbush reiterated an “outperform” rating and issued a $33.00 price target (up from $27.00) on shares of Xencor in a report on Thursday, March 2nd. Finally, Instinet assumed coverage on Xencor in a report on Wednesday, March 1st. They issued a “neutral” rating and a $21.00 price target for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $28.67.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/26/0-25-eps-expected-for-xencor-inc-xncr-this-quarter.html.

In other news, Director Bruce L. A. Carter sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $20.61, for a total value of $412,200.00. Following the completion of the sale, the director now directly owns 48,880 shares in the company, valued at approximately $1,007,416.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce L. A. Carter sold 12,400 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $22.19, for a total value of $275,156.00. Following the completion of the sale, the director now owns 83,344 shares of the company’s stock, valued at $1,849,403.36. The disclosure for this sale can be found here. Insiders sold a total of 46,238 shares of company stock valued at $1,037,822 over the last quarter. Company insiders own 4.14% of the company’s stock.

Large investors have recently modified their holdings of the stock. Oberweis Asset Management Inc. purchased a new stake in shares of Xencor during the fourth quarter worth $211,000. Airain ltd bought a new position in shares of Xencor during the first quarter worth approximately $213,000. Algert Global LLC bought a new position in shares of Xencor during the first quarter worth approximately $284,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Xencor during the fourth quarter worth approximately $370,000. Finally, Clinton Group Inc. increased its position in shares of Xencor by 4.6% in the first quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 700 shares during the last quarter. Institutional investors and hedge funds own 75.00% of the company’s stock.

Xencor (NASDAQ XNCR) traded down 1.09% during mid-day trading on Monday, reaching $21.72. 287,997 shares of the company were exchanged. The stock has a 50-day moving average of $21.90 and a 200 day moving average of $23.80. The firm has a market capitalization of $1.01 billion, a P/E ratio of 61.53 and a beta of 2.13. Xencor has a 1-year low of $12.51 and a 1-year high of $29.38.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.